Healthcare

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on…

9 months ago

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement…

9 months ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,…

9 months ago

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and…

9 months ago

Mednition Appoints Deena Brecher as Chief Nursing Officer, Pioneering Commitment to Nurse-First Artificial Intelligence

BURLINGAME, Calif.--(BUSINESS WIRE)--#AI--Mednition, a Silicon Valley leader in clinical artificial intelligence (AI) healthcare solutions, is excited to announce the appointment…

9 months ago

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

  Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous…

9 months ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first…

9 months ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.  SIMLANDI is the first…

9 months ago

Foothold Technology and NY Health Home Coalition Respond to the Impact Budget Cuts Will Have for Vulnerable New Yorkers

NEW YORK--(BUSINESS WIRE)--In response to the recent executive budget decision by Governor Kathy Hochul, which includes a substantial $125 million…

9 months ago

CGFNS International Unveils New Think Tank to Advance Health Workforce Development Scholarship and Solutions Worldwide 

PHILADELPHIA, PA / ACCESSWIRE / February 23, 2024 / CGFNS International announced today it has established a Global Health Workforce…

9 months ago